BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9687212)

  • 1. Current status of the FDA approval process: comparison of requirements for pediatric and adult patients.
    Robie-Suh KM
    Inflamm Bowel Dis; 1998 May; 4(2):103-4. PubMed ID: 9687212
    [No Abstract]   [Full Text] [Related]  

  • 2. Pediatric testing of prescription drugs: the Food and Drug Administration's carrot and stick for the pharmaceutical industry.
    Karst KR
    Am Univ Law Rev; 2000; 49():739-72. PubMed ID: 11067732
    [No Abstract]   [Full Text] [Related]  

  • 3. Bolstering the FDA's drug-safety authority.
    Schultz WB
    N Engl J Med; 2007 Nov; 357(22):2217-9. PubMed ID: 18046024
    [No Abstract]   [Full Text] [Related]  

  • 4. US regulation of pharmaceutical outcomes research.
    Burke LB
    Value Health; 2001; 4(1):5-7. PubMed ID: 11704971
    [No Abstract]   [Full Text] [Related]  

  • 5. Children, drugs, and the Food and Drug Administration: studies of pediatric drugs are beginning to catch up.
    Ward RM
    Pediatr Ann; 2001 Apr; 30(4):189-94. PubMed ID: 11303433
    [No Abstract]   [Full Text] [Related]  

  • 6. The pediatric research equity act and oncology.
    Hirschfeld S
    Pediatr Blood Cancer; 2004 Aug; 43(2):99-102. PubMed ID: 15236272
    [No Abstract]   [Full Text] [Related]  

  • 7. FDA set to expand pediatric information in drug product labeling.
    Am J Health Syst Pharm; 1995 Feb; 52(4):358. PubMed ID: 7757855
    [No Abstract]   [Full Text] [Related]  

  • 8. Impact of new regulations for pediatric labeling by the Food and Drug Administration.
    Buck ML
    Pediatr Nurs; 2000; 26(1):95-6. PubMed ID: 12026326
    [No Abstract]   [Full Text] [Related]  

  • 9. FDA to require pediatric studies for drugs commonly used in children.
    Miller JL
    Am J Health Syst Pharm; 1999 Feb; 56(3):203. PubMed ID: 10030499
    [No Abstract]   [Full Text] [Related]  

  • 10. FDA proposes more stringent pediatric-use labeling of prescription drug products.
    Am J Hosp Pharm; 1993 Jan; 50(1):13, 16. PubMed ID: 8427271
    [No Abstract]   [Full Text] [Related]  

  • 11. Analgesics for the treatment of pain in children.
    Birenbaum D; Mattison DR
    N Engl J Med; 2003 Mar; 348(10):959-60; author 959-60. PubMed ID: 12621144
    [No Abstract]   [Full Text] [Related]  

  • 12. Revised FDA labeling guideline for theophylline oral dosage forms.
    Hendeles L; Jenkins J; Temple R
    Pharmacotherapy; 1995; 15(4):409-27. PubMed ID: 7479193
    [No Abstract]   [Full Text] [Related]  

  • 13. FDA proposes more stringent pediatric-use labeling of prescription drug products.
    Clin Pharm; 1993 Jan; 12(1):6. PubMed ID: 8428434
    [No Abstract]   [Full Text] [Related]  

  • 14. FDA notifications. Lopinavir/ritonavir label updated.
    AIDS Alert; 2008 Aug; 23(8):92. PubMed ID: 18727173
    [No Abstract]   [Full Text] [Related]  

  • 15. New pediatric dosage rules: information and testing.
    Feeg VD
    Pediatr Nurs; 1998; 24(6):518, 613. PubMed ID: 10085992
    [No Abstract]   [Full Text] [Related]  

  • 16. Adolescent dosing and labeling since the Food and Drug Administration Amendments Act of 2007.
    Momper JD; Mulugeta Y; Green DJ; Karesh A; Krudys KM; Sachs HC; Yao LP; Burckart GJ
    JAMA Pediatr; 2013 Oct; 167(10):926-32. PubMed ID: 23921678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of US Food and Drug Administration-Approved Pediatric Labeling on Dispensing of Extended-Release Oxycodone in the Outpatient Retail Setting.
    Xu J; Gill R; Cruz M; Staffa J; Lurie P
    JAMA Pediatr; 2016 Nov; 170(11):1103-1104. PubMed ID: 27612007
    [No Abstract]   [Full Text] [Related]  

  • 18. Improving pediatric dosing through pediatric initiatives: what we have learned.
    Rodriguez W; Selen A; Avant D; Chaurasia C; Crescenzi T; Gieser G; Di Giacinto J; Huang SM; Lee P; Mathis L; Murphy D; Murphy S; Roberts R; Sachs HC; Suarez S; Tandon V; Uppoor RS
    Pediatrics; 2008 Mar; 121(3):530-9. PubMed ID: 18310202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA notifications. New labeling for Videx pediatric powder.
    AIDS Alert; 2009 Aug; 24(8):94-6. PubMed ID: 19705588
    [No Abstract]   [Full Text] [Related]  

  • 20. Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients--FDA. Final rule.
    Fed Regist; 1998 Dec; 63(231):66631-72. PubMed ID: 10338880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.